文献速递脊柱关节炎其他结缔组织病

阿普米司特治疗免疫检查点抑制剂相关银屑病及银屑病关节炎的应用

Use of Apremilast for the Treatment of Immune Checkpoint Inhibitor Psoriasis and Psoriatic Arthritis.
PubMed 文献 · Arthritis Care Res (Hoboken) · 2025-08-27

这项多中心研究纳入21例免疫检查点抑制剂相关银屑病关节炎(ICI-PsA)和/或银屑病(ICI-PsO)患者,评估阿普米司特的疗效与耐受性。结果显示,新发ICI-PsO和/或ICI-PsA仅5例,其中4例部分缓解但3例不耐受;在有既存自身免疫病且未预先使用阿普米司特的13例中,ICI-PsO-only组100%缓解而ICI-PsA组仅57%缓解。全队列29%因不耐受停药,38%在末次随访时出现癌症进展或死亡。

要点

  • 新发ICI-PsO和/或ICI-PsA仅5例,4例部分缓解但3例不耐受。
  • 既存自身免疫病未预先用药者中,ICI-PsO-only组100%缓解,ICI-PsA组57%缓解。
  • 全队列29%因不耐受停用阿普米司特,38%末次随访时癌症进展或死亡。

核心结论

  • 阿普米司特对ICI-PsO(新发和银屑病 flare)可能有潜在获益,对ICI-PsA的获益似乎较小。
  • 全组30%患者因不耐受停用阿普米司特。
  • 鉴于阿普米司特不具有免疫抑制作用,它可能对这两种情况都是一个有吸引力的治疗选择,但需要更大样本量的进一步前瞻性观察性研究。

研究设计与样本

  • 多中心研究,纳入21例在接受ICI治疗后出现ICI-PsO和/或ICI-PsA并使用阿普米司特的患者。
  • 纳入标准还包括在ICI开始前已使用阿普米司特的患者,以及在ICI治疗前已有自身免疫病的患者。
  • 阿普米司特应答根据用药后常见不良事件评价标准(CTCAE)分级的改善判定为完全、部分或无应答。

主要发现

  • 21例患者中仅5例为新发ICI-PsO和/或ICI-PsA,其中4例部分缓解或免疫相关不良事件改善,但3例存在不耐受。
  • 21例中16例有相关既存自身免疫病,提示ICI治疗可能诱发了基础疾病 flare。
  • ICI-PsA患者 flare 出现时间(4周)远早于单纯ICI-PsO患者(39.7周),但两组多数均为II级严重程度。
  • 在13例有既存疾病且ICI治疗前未使用阿普米司特的患者中,ICI-PsO-only组全部(100%)达到完全或部分缓解,而ICI-PsA组仅57%达到完全或部分缓解。
  • 全队列29%因不耐受停用阿普米司特;全队列38%在阿普米司特治疗后的末次随访时出现癌症进展或死亡。

临床怎么用

  • 作者认为阿普米司特对ICI-PsO(新发和银屑病 flare)可能有潜在获益,对ICI-PsA的获益似乎较小。
  • 作者认为鉴于阿普米司特不具有免疫抑制作用,它可能对这两种情况都是一个有吸引力的治疗选择,但需要更大样本量的进一步前瞻性观察性研究。

局限性

  • 需要更大样本量的进一步前瞻性观察性研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The objective of this study was to present effectiveness and tolerability of apremilast in a cohort of 21 patients with immune checkpoint inhibitor psoriatic arthritis (ICI-PsA) and/or immune checkpoint inhibitor psoriasis (ICI-PsO). METHODS: This multicenter study combined data from patients treated with apremilast after experiencing ICI-PsO and/or ICI-PsA. Patients taking apremilast before ICI initiation and patients with preexisting autoimmune disease before ICI therapy were also included. Response to apremilast was determined as complete, partial, or none as determined by improvement in Common Terminology Criteria for Adverse Events grading after drug initiation. RESULTS: There were 21 patients who used apremilast for either ICI-PsO and/or ICI-PsA, but only five of these patients had de novo ICI-PsO and/or ICI-PsA. Of these five patients, four had partial response or improvement in their immune-related adverse event with apremilast, although there were intolerances in three of these patients. Of the 21 total patients, 16 had a relevant preexisting autoimmune disease, indicating a likely flare of the underlying disease with ICI therapy. Flares occurred much sooner for patients with ICI-PsA (4 weeks) compared to patients with ICI-PsO only (39.7 weeks), although the majority of both groups had grade II severity. Among the 13 patients with preexisting disease and no exposure to apremilast before ICI therapy, all patients in the ICI-PsO-only group (100%) responded to apremilast with either a complete or partial response, whereas only 57% of patients in the ICI-PsA group had complete or partial response. Twenty-nine percent of patients in the entire cohort had to discontinue apremilast due to intolerability. Thirty-eight percent of the entire cohort had progression of cancer or death at last follow-up after being on apremilast. CONCLUSION: This study highlights the potential benefit of apremilast for the treatment of ICI-PsO, both de novo and PsO flare, with less of an apparent benefit for ICI-PsA. Thirty percent of patients in the whole group had to discontinue apremilast due to intolerance. Apremilast may be an attractive therapeutic option for either condition given that it is not immunosuppressive, but further prospective observational studies with larger patient numbers are needed.

来源:Arthritis Care Res (Hoboken),查看原文。版权归原作者所有。

引用

  1. Ghosh N, Reid P, Sparks JA, et al. Use of Apremilast for the Treatment of Immune Checkpoint Inhibitor Psoriasis and Psoriatic Arthritis. Arthritis Care Res (Hoboken). 2025. PMID: 40865544. doi:10.1002/acr.25604

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。